Evidence map›Paper›PMID 26590947›Full record

ArticleImmunologic research2016

Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02:01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients.

Sergey Vital'evich Sennikov, Julia Alexandrovna Shevchenko, Vasilii Vasil'evich Kurilin, Julia Nikolaevna Khantakova, Julia Anatol'evna Lopatnikova, Elena Vasil'evna Gavrilova, Rinat Amirovich Maksyutov, Anastasiya Yur'evna Bakulina, Sergey Vasil'evich Sidorov, Alexander Alexandrovich Khristin and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sergey Vital'evich SennikovDepartment of Molecular Immunology, Federal State Budgetary Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya St. 14, Novosibirsk, Novosibirsk, Russia, 630099. sennikovsv@gmail.com.
Julia Alexandrovna ShevchenkoDepartment of Molecular Immunology, Federal State Budgetary Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya St. 14, Novosibirsk, Novosibirsk, Russia, 630099.
Vasilii Vasil'evich KurilinDepartment of Molecular Immunology, Federal State Budgetary Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya St. 14, Novosibirsk, Novosibirsk, Russia, 630099.
Julia Nikolaevna KhantakovaDepartment of Molecular Immunology, Federal State Budgetary Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya St. 14, Novosibirsk, Novosibirsk, Russia, 630099.
Julia Anatol'evna LopatnikovaDepartment of Molecular Immunology, Federal State Budgetary Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya St. 14, Novosibirsk, Novosibirsk, Russia, 630099.
Elena Vasil'evna GavrilovaVaccine Department, Avaxis Biotherapeutics LLC, Technopark St. 1 116, Koltsovo, Novosibirsk Region, Russia, 630559.
Rinat Amirovich MaksyutovVaccine Department, Avaxis Biotherapeutics LLC, Technopark St. 1 116, Koltsovo, Novosibirsk Region, Russia, 630559.
Anastasiya Yur'evna BakulinaNovosibirsk State University, Pirogova-90 St. 1, Novosibirsk, Russia.
Sergey Vasil'evich Sidorov3rd Oncological Department, City Clinical Hospital #1, Zalessky St. 6, Siberian Field, Novosibirsk, Russia, 630047.
Alexander Alexandrovich KhristinDepartment of Molecular Immunology, Federal State Budgetary Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya St. 14, Novosibirsk, Novosibirsk, Russia, 630099.
Amir Zakievich MaksyutovVaccine Department, Avaxis Biotherapeutics LLC, Technopark St. 1 116, Koltsovo, Novosibirsk Region, Russia, 630559.
Research Institute of Fundamental and Clinical Immunology · RUCity Clinical Hospital No. 2 · RUNovosibirsk State University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in oncoimmunology related to the definition of the basic mechanisms of the formation of antitumor immune response, as well as the opening of tumor-associated antigens recognized by immune cells, allowed to start developing ways to influence the effector cells of the immune system to generate effective antitumor cytotoxic response. We investigated the possibility to stimulate an antitumor response in a culture of mononuclear cells of breast cancer patients by dendritic cells transfected with HLA-A*02:01-restricted DNA constructs. We isolated dendritic cells from peripheral blood monocytes and delivered our constructs to these cells by magnetic transfection. Additionally, a series of experiments with loading of dendritic cells with autologous tumor cell lysate antigens was conducted. We have shown that dendritic cells transfected with the HLA-A*02:01-restricted DNA constructs are effective in inducing an antitumor response in a culture of mononuclear cells of breast cancer patients. Dendritic cells transfected with DNA constructor dendritic cells loaded with lysate antigens revealed a comparable stimulated cytotoxic response of mononuclear cells to these two ways of antigen delivery. We conclude that using DNA constructs in conjunction with patient stratification by HLA type allows the application of transfected DCs as an effective method to stimulate antitumor immunity in vitro.

Indexed as

Amino Acid SequenceAntigens, NeoplasmBreast NeoplasmsCancer VaccinesCells, CulturedCoculture TechniquesCytotoxicity, ImmunologicDendritic CellsFemaleHLA-A2 AntigenHumansImmunodominant EpitopesImmunotherapyLeukocytes, MononuclearTransfectionAntigens, NeoplasmCancer VaccinesHLA-A*02:01 antigenHLA-A2 AntigenImmunodominant EpitopesBreast cancerCytotoxicityDendritic cellsDNA constructsTransfection

Identifiers

PMID26590947
OpenAlexW2316260899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.